Clinical Trial Update: A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of HIV agent BMS-626529 when dosed as the prodrug BMS-663068 from two extended-release tablet strengths; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• BMS-626529
• BMS-663068 (BMS-626529)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED